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Transplanted nonviable human hepatocytes produce
appreciable serum albumin levels in mice
Garrett R. Roll a,⁎, Holger Willenbring a,b,ca Department of Surgery, Division of Transplantation, University of California San Francisco, 513 Parnassus Avenue,
San Francisco, CA 94143, USA
b Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California San Francisco,
513 Parnassus Avenue, San Francisco, CA 94143, USA
c Liver Center, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USAReceived 27 May 2010; received in revised form 24 July 2010; accepted 28 July 2010Abstract In animal models of liver cell therapy serum human albumin levels are universally measured as a marker for
the engraftment and function of transplanted human hepatocytes, or hepatocyte-like cells derived from human stem
cells. However, even the most efficient cell transplantation protocols encounter a significant amount of graft cell death.
If albumin released from dying cells could be detected for prolonged periods of time in the serum of the recipient, it
may misleadingly suggest engraftment and function of the transplanted cells. While a half-life of approximately 20 days
of human albumin in humans is established, the duration of its detectability in mice is unknown. Here we show that human
albumin is readily detectable in the serum of mice injected with nonviable human hepatocytes. Human albumin levels peak
24 h after injection of hepatocyte debris, and remain detectable at significant levels for at least 8 days. Our finding
suggests that long-term, or in situ, analyses are needed to prove functional engraftment of human primary or stem
cell-derived hepatocytes.
© 2010 Elsevier B.V. All rights reserved.Introduction
Hepatocyte infusion is an alternative to whole liver transplan-
tation, but its potential is limited by a shortage of donor
hepatocytes (Ito et al., 2009; Fisher and Strom, 2006).
Advances in the directed differentiation of stem cells into
hepatocytes continue to bring cell therapy for liver diseases
closer to large-scale clinical utility (Cai et al., 2007; Hay et al.,Abbreviations: SHA, serum human albumin; ip, intraperitoneal.
⁎ Corresponding author. Department of Surgery, 513 Parnassus
Avenue, S-321, San Francisco, CA 94143, USA. Fax: +1 415 502 1259.
E-mail addresses: Garrett.Roll@ucsfmedctr.org (G.R. Roll),
willenbringh@stemcell.ucsf.edu (H. Willenbring).
1873-5061/$ – see front matter © 2010 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2010.07.0042008; Basma et al., 2009; Si-Tayeb et al., 2010; Touboul et al.,
2010; Duan et al., 2010). Immunodeficient animal models of
liver diseases provide powerful experimental systems for
evaluating the efficacy of liver cell therapies with hepato-
cyte-like cells derived from human embryonic and induced
pluripotent stem cells (Tateno et al., 2004, Azuma et al.,
2007). In addition, the therapeutic potential of hepatocytes
derived from human adult or fetal stem cells can be evaluated
in suchmodels (Wang et al., 2003; Mahieu-Caputo et al., 2004;
Aurich et al., 2003). Currently, analysis of the ability of all of
these cell types to engraft in the liver, provide hepatocyte
function, and potentially expand relies mainly on the
measurement of serum human albumin (SHA) as a readout.
Besides reflecting the level of hepatocyte differentiation and
therapeutic potential of cells derived from stem cells, SHA is
also useful as a marker for the function of bioartificial liver.
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(Wurm et al., 2010; Varo Perez and Castroagudin, 2010).
While the half-life of SHA in humans is known to be
approximately 20 days (Peters, 1970), the half-life of SHA in
mice has not been reported. Albumin-producing cells that
die during cell preparation or after transplantation could
release this protein, potentially confounding serum analyses
of the recipient. If that was true, prolonged detection of SHA
in mice could falsely indicate that transplanted human stem
cell-derived hepatocytes successfully engrafted in the liver
and are providing normal liver function. To address this
uncertainty, we injected nonviable human hepatocytes into
the abdomen of mice and followed the levels of human
albumin in their sera.
Results
Aliquots of either human or mouse hepatocytes were
resuspended in distilled water to create a lysate of 100%
nonviable cells that would be unable to engraft (Fig. 1A). The
albumin concentration of the human hepatocyte lysate was
37,241 ng/ml, and as expected, the lysate of nonviable
mouse hepatocytes contained no detectable human albumin
(data not shown). The nonviable cell suspensions were
injected intraperitoneally (ip) into separate wild-type mice
and SHA levels were followed over time. The level of human
albumin detected in the serum of mice injected with human
hepatocyte lysate was 2096 ng/ml 2 h after injection
(Fig. 1B). The SHA levels peaked 24 h after injection atFigure 1 Human albumin levels released from nonviable
human hepatocytes. (A) Failure to exclude trypan blue shows
that no viable hepatocytes remain prior to ip injection. Size
bar=75 μm. (B) Mean SHA detectable in 3 mice 0, 2, 24, 96, 192,
and 288 h after ip injection of nonviable human hepatocytes.
Error bars represent average±SD.3117 ng/ml before beginning to decline. The amount of
78.9 ng/ml of SHA was still detectable 8 days after injection.
No SHA was present 12 days after injection. Normal renal
function parameters excluded that hepatocyte transplanta-
tion-induced acute renal failure was responsible for the
prolonged persistence of SHA in mice (Supplementary
Figs. 1A and B). As expected, no SHA was identified at any
time in mice injected with nonviable mouse hepatocytes, or
mice injected only with PBS (data not shown).
Discussion
Albumin is produced solely by hepatocytes. It serves as the
major depot and carrier protein for hydrophobic substances
in the blood such as bilirubin, long-chain fatty acids, and
pharmaceutical agents, and can be used clinically to restore
plasma volume by maintaining oncotic pressure (Kragh-
Hansen, 1981). Much of the utility of this protein in biological
systems rests on its long serum half-life. Similarly, the long
half-life of albumin in the serum is commonly harnessed in
drug delivery strategies to achieve prolonged and reproduc-
ible pharmacokinetics (Muller et al., 2010; Constantinou
et al., 2010; Schulte, 2009; Kratz, 2008).
The constitutive production of albumin by hepatocytes is
used extensively as a marker in vitro, and in vivo, to
determine the presence and function of hepatocytes or
hepatocyte-like cells. When these cells are transplanted into
animal cell therapy models, human albumin in the serum of
the recipient suggests that the transplanted cells have
engrafted and are functionally active.
Even after optimal hepatocyte preparation, only 10–30%
of transplanted hepatocytes engraft and persist in the liver
(Gupta et al., 1991; Joseph et al., 2002; Rajvanshi et al.,
1996; Han et al., 2009). Thus, 70–90% of the transplanted
hepatocytes die, releasing albumin into the recipient's blood
and potentially compromising serum analysis. Our results
show that human albumin released from nonviable human
hepatocytes, incapable of engraftment or function, can
be detected in the serum of recipient mice for at least
8 days. Thus, after transplantation of human hepatocytes
or hepatocyte-like cells, SHA can derive not only from
functional graft cells, but also from albumin-producing
cells that have died for any reason in the preceding
week.
Conclusion
Human albumin released from dead human hepatocytes
injected into the peritoneal cavity can be detected in the
serum of recipient mice. The human albumin in the serum of
these mice peaks around 24 h, and can be detected at
significant levels for at least 8 days. Therefore, SHA cannot
be used to quantify the engraftment of viable hepatocytes
early after transplantation. Thus, in short-term but also in
long-term experiments in liver cell therapy models, analysis
of serummarkers of hepatocyte function should be combined
with hepatocyte-specific immunohistochemical stainings to
prove successful engraftment and differentiated function of
transplanted cells. In summary, the release of relatively
stable human albumin from dead or nonengrafted cells must
be taken into account when SHA is used to quantify the
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human bioartificial liver systems in animal models.
Materials and methods
Human hepatocytes
Primary human hepatocytes were obtained from a human
donor organ unsuitable for cadaveric liver donation. Cells
were purified and then purchased as a cell suspension
(Lonza, Walkersville, Inc.).
Isolation of mouse hepatocytes
Single-cell suspensions of hepatocytes were isolated from
mouse liver on the C57BL/6 strain by perfusion through a 24-
gauge intraportal catheter (Surflo, Terumo) with Earle's
basic salt solution (EBSS, Invitrogen) plus 0.5 mM EGTA and
10 mM Hepes (both Sigma), followed by EBSS plus 0.1 mg/ml
Liberase Blendzyme 3 (Roche). Hepatocytes were released
from the liver capsule and filtered through a 70-μm cell
strainer (BD Falcon). Gravity sedimentation on ice for
20 min, followed by a second round of filtration and
sedimentation, was used to enrich viable hepatocytes to
approximately 95%, as confirmed by trypan blue (Sigma)
exclusion. All procedures involving mice were approved by
the Institutional Animal Care Committee at the University of
California San Francisco.
Preparation of nonviable human or mouse
hepatocytes
To produce nonviable hepatocytes for transplantation, ali-
quots of 1×106 human ormouse hepatocytes were centrifuged
and then flash-frozen in liquid nitrogen. To ensure 100% death
of the transplanted hepatocytes, aliquots of frozen cells were
resuspended in 750 μl of distilled water for 60 min at room
temperature and then vortexed for 10 s. Hepatocyte death
was assessed by trypan blue exclusion (Sigma) (Fig. 1A), an
established marker of irreversible plasma membrane break-
down (Galluzzi et al., 2009). Ten randomly selected high-
powered fields of human and mouse hepatocyte lysate were
analyzed and no viable cells were observed (data not shown).
Transplantation
Lysates from 1×106 human hepatocytes, or 1×106 mouse
hepatocytes, were transplanted by intraperitoneal injection
into 10-week-old mice on the 129 S4 strain background. To
prevent hyponatremia from the excess freewater in the lysate
injection, 750 μl of phosphate buffered saline (PBS), pH 7.4
(Gibco), was given ip. Control mice not undergoing injection
of human or mouse hepatocytes were given 1.5 ml of PBS ip.
Serum human albumin determinations
Blood was obtained by retroorbital phlebotomy. All samples
were quantified in triplicate using a human albumin enzyme-
linked immunosorbent assay (ELISA, Bethyl Laboratories).
Human albumin concentrations were calculated based on theequation: y=((A–D)/(1+(x/C^B))+D, as described by the
assay supplier, using intensity-based correction followed by
normalization to known values of an internal standard
(Hamelinck et al., 2005).
Statistical analysis
Statistical significance was determined using Student's
t tests.
Supplementary materials related to this article can be
found online at doi:10.1016/j.scr.2010.07.004.Acknowledgments
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